[go: up one dir, main page]

ATE476496T1 - Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten - Google Patents

Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten

Info

Publication number
ATE476496T1
ATE476496T1 AT97914841T AT97914841T ATE476496T1 AT E476496 T1 ATE476496 T1 AT E476496T1 AT 97914841 T AT97914841 T AT 97914841T AT 97914841 T AT97914841 T AT 97914841T AT E476496 T1 ATE476496 T1 AT E476496T1
Authority
AT
Austria
Prior art keywords
modified
rem
lymphocytes
pbmc
rapid development
Prior art date
Application number
AT97914841T
Other languages
English (en)
Inventor
David Flyer
Kim Clary
Original Assignee
Calyx Bio Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calyx Bio Ventures Inc filed Critical Calyx Bio Ventures Inc
Priority claimed from PCT/US1997/003293 external-priority patent/WO1997032970A1/en
Application granted granted Critical
Publication of ATE476496T1 publication Critical patent/ATE476496T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AT97914841T 1996-03-04 1997-03-03 Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten ATE476496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3733396P 1996-03-04 1996-03-04
PCT/US1997/003293 WO1997032970A1 (en) 1996-03-04 1997-03-03 Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes

Publications (1)

Publication Number Publication Date
ATE476496T1 true ATE476496T1 (de) 2010-08-15

Family

ID=21893787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914841T ATE476496T1 (de) 1996-03-04 1997-03-03 Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten

Country Status (5)

Country Link
US (3) US6316257B1 (de)
EP (1) EP0904350B1 (de)
JP (1) JP2002516562A (de)
AT (1) ATE476496T1 (de)
DE (1) DE69739951D1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2003534283A (ja) * 2000-05-25 2003-11-18 エクサイト セラピーズ， インコーポレイテッド 天然で誘導されたかまたは人工的に誘導された免疫抑制後にｔ細胞免疫サーベイランスを回復もしくは増強するための方法
EP1312670A4 (de) * 2000-08-16 2005-11-30 Takara Bio Inc Methode zur extensiven kultur von antigen-spezifischen cytotoxischen t-zellen
EP1390076A4 (de) * 2001-04-27 2004-12-15 Xcyte Therapies Inc Reifung antigen-präsentierender zellen mit aktivierten zellen
KR20040048379A (ko) * 2001-06-01 2004-06-09 싸이트 테라피스 인코포레이티드 Ｔ 세포 유도된 조직 복구 및 재생
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
TWI315740B (de) * 2001-08-15 2009-10-11 Takara Bio Inc
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
AU2003216436A1 (en) * 2002-02-08 2003-09-02 Life Technologies Corporation Compositions and methods for restoring immune responsiveness in patients with immunological defects
DE60335253D1 (de) * 2002-03-25 2011-01-20 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1596871A4 (de) * 2003-02-28 2006-08-23 Drew M Pardoll T-zell-regulierung
CA2525519A1 (en) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
KR101331746B1 (ko) 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
US20050118173A1 (en) * 2003-09-22 2005-06-02 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
CA2552891A1 (en) * 2004-01-08 2005-08-04 Regents Of The University Of California Regulatory t cells suppress autoimmunity
EP3067415A1 (de) * 2004-02-26 2016-09-14 Immunovative Therapies, Ltd. Verfahren zur herstellung von t-zellen zur zelltherapie
CA2568344C (en) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1812563B1 (de) * 2004-10-29 2013-04-10 Benaroya Research Institute at Virginia Mason Verfahren zur herstellung antigenspezifischer cd4+cd25+-regulator-t-zellen, zusammensetzungen und verwendungsverfahren
LT1814580T (lt) 2004-11-24 2016-12-12 Fred Hutchinson Cancer Research Center Il 21 naudojimo pritaikomajai imunoterapijai ir naviko antigenų identifikavimo metodai
EP1916302A4 (de) * 2005-08-17 2009-10-21 Takara Bio Inc Verfahren zur herstellung von lymphozyten
EP1941027B1 (de) * 2005-09-28 2014-08-20 IPD-Therapeutics B.V. Methoden und mittel zur vermehrung von stammzellen und anschliessenden generierung und vermehrung von vorläuferzellen; produktion von effektorzellen als klinische therapeutika
WO2007040105A1 (ja) * 2005-09-30 2007-04-12 Takara Bio Inc. Ｔ細胞集団の製造方法
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
AU2008262487B2 (en) 2007-05-23 2013-10-31 Sangamo Therapeutics, Inc. Methods and compositions for increased transgene expression
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
CN101883844A (zh) 2007-10-12 2010-11-10 分子医学马克斯德尔布吕克中心 快速分离人Foxp3+Treg细胞的方法和试剂盒
ATE493491T1 (de) * 2007-10-12 2011-01-15 Max Delbrueck Centrum Verfahren und kit zur schnellen isolierung humaner foxp3-treg-zellen
KR20090127973A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양 방법
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
US8467973B2 (en) * 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
US8558913B2 (en) * 2010-02-08 2013-10-15 Apple Inc. Capture condition selection from brightness and motion
DK2694640T3 (da) * 2011-04-08 2017-11-20 Baylor College Medicine Reversion af effekterne af tumormikromiljø ved anvendelse af kimæriske cytokinreceptorer
CA3083118A1 (en) * 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
EP4463549A2 (de) 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur programmierung von t-zell-phänotypen durch gezielte genunterdrückung
EP4463548A1 (de) 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur programmierung von t-zell-phänotypen durch gezielte genaktivierung
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544632A (en) 1981-06-12 1985-10-01 Yuichi Yamamura Human T cell lines and method of producing same
JPS59169489A (ja) 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
EP0147689B1 (de) 1983-12-05 1990-09-19 Asahi Kasei Kogyo Kabushiki Kaisha Verfahren zur Induktion von Antitumorimmunozyten, Verfahren zur Herstellung von Antitumorimmunozyten und durch das Verfahren hergestellte Antitumorimmunozyten
JPH02502424A (ja) 1987-03-11 1990-08-09 ザ・チルドレンズ・ホスピタル，インコーポレイテッド 抗原特異的ｔセルラインの調製法並びに治療のためのその使用
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ZA91463B (en) 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
DE69131577T2 (de) 1990-09-28 2000-05-04 Fred Hutchinson Cancer Research Center, Seattle Verfahren zur herstellung th-unabhängiger zytotoxischer t-zymphozyten
AU650085B2 (en) 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
DE4410136A1 (de) 1993-03-31 1994-10-06 Boehringer Mannheim Gmbh Tumorizide T-Lymphozyten
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ES2236719T3 (es) * 1994-11-17 2005-07-16 University Of South Florida Metodo para fabricar un medicamento para el tratamiento de la inmunodeficiencia secundaria.

Also Published As

Publication number Publication date
DE69739951D1 (de) 2010-09-16
US20050164387A1 (en) 2005-07-28
EP0904350B1 (de) 2010-08-04
US6890753B2 (en) 2005-05-10
JP2002516562A (ja) 2002-06-04
EP0904350A1 (de) 1999-03-31
US20020197716A1 (en) 2002-12-26
US6316257B1 (en) 2001-11-13

Similar Documents

Publication Publication Date Title
ATE476496T1 (de) Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
ES2185649T3 (es) Inhibidores de la proliferacion de las celulas germinales y sus utilizaciones.
MX9203439A (es) Una citocina mamifera, il-11
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
AR053946A2 (es) Variante de alfa-amilasa de bacillus stearothermophilus original
EP0789588A4 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
GEP20001969B (en) Benzothiazine Dioxides as Endothelinn Antagonists
ATE68001T1 (de) 11-beta-nitrat-substituierte estrane.
HK1028615A1 (en) Isolated nona-and decapeptides which bind to hla molecules, and the use thereof
ES2191065T3 (es) Linfocitos t dirigidos.
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
ES2175181T3 (es) Analogos hexaciclicos de camptotecina y su procedimiento de preparacion.
IT8622548A0 (it) Procedimento d'epurazione e di deodorizzazione di gas e installazione per la messa in opera di questo procedimento.
FR2689518B1 (fr) Microorganismes, procédé de préparation et utilisation.
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
DE69428909D1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
WO1989005644A3 (fr) Thienotricyclene
ATE75610T1 (de) Pharmazeutische zubereitung zur behandlung des bluthochdrucks.
BG89739A (bg) Метод за повишаване ензимната активност и синтезната продуктивност на организми
DE69504299D1 (de) Schneller Vermittler und Schnelles Vermittlungsverfahren
FR2604905B1 (fr) Procede d'obtention d'un epithelium gingival equivalent a partir de cellules humaines cultivees in vitro ainsi que les applications de cet epithelium en odontologie-stomatologie
ATE200424T1 (de) Verwendung von bk-riv-präparaten als arzneimittel zur therapie von aids
MX9800891A (es) Mocarhagina, una proteasa del veneno de cobra y usso terapeuticos de la misma.
UA9690A (uk) Індуктор інтерферону першого типу в культурах клітин
IT1217825B (it) Procedimento ed impianto per la coltura di microorganismi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties